Bascom Palmer Eye Institute, University of Miami, Miami, FL 33136, USA.
Int J Mol Sci. 2022 May 20;23(10):5751. doi: 10.3390/ijms23105751.
The goal of neuroprotection in optic neuropathies is to prevent loss of retinal ganglion cells (RGCs) and spare their function. The ideal time window for initiating neuroprotective treatments should be the preclinical period at which RGCs start losing their functional integrity before dying. Noninvasive electrophysiological tests such as the Pattern Electroretinogram (PERG) can assess the ability of RGCs to generate electrical signals under a protracted degenerative process in both clinical conditions and experimental models, which may have both diagnostic and prognostic values and provide the rationale for early treatment. The PERG can be used to longitudinally monitor the acute and chronic effects of neuroprotective treatments. User-friendly versions of the PERG technology are now commercially available for both clinical and experimental use.
神经保护在视神经病变中的目标是防止视网膜神经节细胞(RGC)的损失并保留其功能。开始神经保护治疗的理想时间窗口应该是在 RGC 开始丧失其功能完整性之前的临床前阶段。非侵入性电生理学测试,如图形视网膜电图(PERG),可以评估 RGC 在临床情况和实验模型中延长的退行性过程中产生电信号的能力,这可能具有诊断和预后价值,并为早期治疗提供依据。PERG 可用于纵向监测神经保护治疗的急性和慢性效果。现在,PERG 技术的用户友好版本已在临床和实验中广泛使用。